Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients

European Journal of Clinical Pharmacology

Volumn 57, Issue 10, 2001, Pages 723-727

  Csajka, Chantal ^a   Décosterd, Laurent ^a   Buclin, Thierry ^a   Pagani, Jean Luc ^a   Fattinger, Karin ^b   Bille, Jacques ^a   Biollaz, Jérôme ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Candidiasis; Fluconazole; HIV; Patients; PK; Population

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; FLUCONAZOLE;

ADULT; AGE; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ARTICLE; BODY WEIGHT; CANDIDIASIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL ABSORPTION; GENDER; HEIGHT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KINETICS; MALE; MINIMUM INHIBITORY CONCENTRATION; OROPHARYNX; PRIORITY JOURNAL; RELAPSE; SECONDARY PREVENTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0035667773     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-001-0377-6     Document Type: Article

References (18)

1. The use of fluconazole and itraconazole in the treatment of Candida albicans infections: A review
2. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS
3. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study
4. Maintenance therapy of oropharyngeal candidiasis in HIV infected patients with fluconazole
5. Once-weekly fluconazole to prevent recurrences of oropharyngeal candidiasis in patients with AIDS or AIDS-related-complex: A double-blind study
6. Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: A pilot study
7. Correlation between in vitro susceptibility of Candida albicans and fluconazole resistant oropharyngeal candidiasis in HIV-infected patients
8. Prediction of creatinine clearance from serum creatinine
9. Determination of fluconazole in human serum by solid-phase extraction and reverse-phase high-performance liquid chromatography
10. Validation of bioanalytical methods
11. The NONMEM system
12. The importance of modelling interoccasion variability in population pharmacokinetic analyses
13. A new look at the statistical model identification
14. Clinical pharmacokinetics of fluconazole
15. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS
16. Pharmacokinetics of fluconazole in people with HIV infection: A population analysis
17. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses
18. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection